ZBTB34 inhibitors are a class of compounds designed to specifically target ZBTB34, a transcription factor from the ZBTB (zinc finger and BTB) family, which plays a critical role in regulating gene expression. ZBTB34 contains two primary functional domains: the zinc finger domain, which enables the protein to bind to specific DNA sequences, and the BTB (Broad-Complex, Tramtrack, and Bric-à-Brac) domain, which is responsible for mediating protein-protein interactions. ZBTB34 is thought to function mainly as a transcriptional repressor, modulating the expression of target genes by binding to promoter regions and recruiting corepressor complexes through its BTB domain. This interaction allows ZBTB34 to influence chromatin structure and gene accessibility, making it a key player in transcriptional regulation. Inhibitors of ZBTB34 work by disrupting either its DNA-binding ability or its capacity to form functional protein complexes, thereby affecting gene expression patterns controlled by this transcription factor.
The mechanisms by which ZBTB34 inhibitors function are varied depending on the chemical properties of the compounds. One common approach is to target the zinc finger domains, which are critical for ZBTB34's DNA-binding activity. Inhibitors may bind to or chelate the zinc ions essential for the structural stability of these motifs, causing the protein to lose its ability to interact with DNA effectively. This prevents ZBTB34 from binding to promoter regions of target genes, ultimately impairing its role in regulating transcription. Another strategy involves inhibiting the BTB domain, which is crucial for protein-protein interactions that allow ZBTB34 to recruit other regulatory proteins or corepressors. By blocking these interactions, inhibitors prevent the assembly of repressive transcriptional complexes, further impairing ZBTB34's ability to control gene expression. The study of ZBTB34 inhibitors provides valuable insights into the broader mechanisms of transcriptional regulation and highlights the importance of zinc finger and BTB domain-containing proteins in maintaining gene expression homeostasis and cellular function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Histone deacetylase inhibitor that can alter chromatin structure and gene expression, potentially affecting ZBTB34 expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA methyltransferase inhibitor that can cause hypomethylation of DNA and influence gene expression, possibly including ZBTB34. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Another histone deacetylase inhibitor that can change gene expression patterns, potentially reducing ZBTB34 expression. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Aldehyde dehydrogenase inhibitor that can modulate protein degradation pathways, possibly impacting ZBTB34 stability. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can prevent the degradation of proteins, potentially affecting the levels of ZBTB34 in the cell. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Selective proteasome inhibitor that can also lead to increased protein levels in cells, including ZBTB34. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Lysosomal inhibitor that can prevent autophagy, potentially impacting ZBTB34 degradation via autophagy. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that can alter MAPK/ERK signaling, potentially affecting ZBTB34's role in these pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can modify stress response and apoptotic pathways, potentially impacting ZBTB34's involvement in these processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor that can change the dynamics of MAPK/ERK signaling, potentially influencing ZBTB34 activity. | ||||||